The review emphasizes that ravulizumab, due to its long-acting C5 inhibition, offers a sustained therapeutic effect in patients with atypical hemolytic uremic syndrome (aHUS), reducing the need for frequent dosing while maintaining efficacy and safety comparable to eculizumab. This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.